XBiotech

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy | XBiotech XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha | XBiotech XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

https://www.xbiotech.com/news/advancing-infectious-disease-innovation

Advancing Infectious Disease Innovation: New Microscopy Insights from Our UT Austin Collaboration | XBiotech XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

XBiotech Pauses Rheumatology program
https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-pauses-rheumatology-program

XBiotech We Believe.

XBiotech We Believe XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technolo...

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer | XBiotech Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind,

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus | XBiotech AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis | XBiotech (Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke | XBiotech AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical

MILESTONE ACHIEVED IN PHASE I CLINICAL TRIAL FOR HUTRUKIN™ STROKE DRUG

** XBiotech.com ** XBiotech